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Implication for health policy/practice/research/medical education:
Farnesol as an antioxidant agent was able to provide some protection against toxic effects of cyclophosphamide especially on 
testes tissues. Hence it might be useful in patients using this drug.
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Introduction: Cyclophosphamide is an alkylating agent with antineoplastic and 
immunosuppressive effects. Acrolein, one of its metabolites, is responsible for different toxic side 
effects such as oxidative stress, and cell death. The present study aimed to evaluate protective 
effects of farnesol, a natural terpenoid with antioxidant effects, on cyclophosphamide induced 
side effects. 
Methods: For this purpose, mice received 200 mg/kg of cyclophosphamide plus 5 or 10 mg/kg 
of farnesol as pretreatment for 7 days. At the end of the study, samples from blood and different 
organs were collected. Histopathological and biochemical analyses including malondialdehyde 
(MDA), catalase (CAT) and glutathione (GSH) content as well as alanine transaminase (ALT) and 
aspartate aminotransferase (AST) were done to determine the toxic effects of cyclophosphamide 
and probable protective effect of farnesol. 
Results: Application of farnesol as a pretreatment could reduce tissue damages induced by 
cyclophosphamide particularly in testis, liver and spleen. The kidney did not show any relapse in 
tissue damages induced by cyclophosphamide. The testis demonstrated the most improvement 
by administration of farnesol, and the anti-oxidant enzymes increased in testicular tissues.
Conclusion: This study indicated the protective effect of farnesol against oxidative stress induced 
by cyclophosphamide in the tissues, especially at the dose of 10 mg/kg on the testicular tissue. 
Hence, it might be beneficial in patients who are using cyclophosphamide. 
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A B S T R A C T
Introduction
Cyclophosphamide (CP; N, N-bis (2-chloroethyl) 
tetrahydro- 2H-1, 3, 2-oxazaphosphorin-2-amine 2-oxide) 
(Figure 1A), is an alkylating agent with antineoplastic 
and immunosuppressive effects used for the treatment 
of malignancies including lymphomas, breast cancer, 
leukemia, multiple myeloma and some diseases such 
as, rheumatoid arthritis, systemic lupus erythematosus 
(SLE), and in blood stem cell transplantation in humans 
and animals (1,2). CP, through bioactivation by hepatic 
microsomal cytochrome P450, produces two active 
metabolites: phosphoramide mustard and acrolein 
(3). The antineoplastic  effects of CP are related to 
phosphoramide mustard, but acrolein is responsible for 
several toxic effects such as, induction of oxidative stress, 
cell death (apoptotic necrosis and oncotic necrosis) (4). 
Alleviation of toxic effects of CP in different organs has 
been investigated by using some antioxidant agents (5-11). 
Farnesol, a 15-carbon sesquiterpene (Figure 1B), is 
produced in cells by dephosphorylation of farnesyl 
pyrophosphate (FPP), a metabolic precursor of squalene 
producing sterols and other isoprenoid compounds. 
Dietary sources of the farnesol are plant products 
including fruits and berries (e.g. apricots, peaches, plums, 
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blueberries, cranberries, raspberries, and strawberries), 
vegetables (e.g. tomatoes), herbs (e.g. lemongrass and 
chamomile). It is also obtained from the essential oils of 
ambrette seeds, and citronella (12). Several studies have 
demonstrated the protective effect of farnesol against 
oxidative stress and reduction of tissue damage (12,13). 
The aim of this study was investigating the protective 
effect of farnesol against toxic effects induced by CP in a 
mouse model.
Materials and Methods
Chemicals
Cyclophosphamide was obtained from Endoxan Baxter® 
Oncology GmbH, Germany. Farnesol was purchased 
from Sigma-Aldrich (St Louis, MO, USA). According 
to Sigma Company, the degree of purity was more than 
97%. Farnesol was emulsified with 0.2% Tween 80 (Sigma, 
USA) for preparation of injection solutions. All other 
chemical substances used in oxidative stress tests were 
analytical grade and commercially available. 
Animals and experiment protocol
The adult male Swiss Albino mice (25-32 g) were 
acclimatized for 7 days before initiation of experiment. 
Mice were given standard chow and tap water ad libitum. 
They were housed in caging system in an air-conditioned 
room with 12/12 h light-dark cycles, where the temperature 
(22±2°C) and relative humidity (60%-65%) were kept 
constant. All animal experimental procedures were under 
rules of the Animal Ethics Committee of Pasteur Institute 
of Iran. The animal protocol was planned to minimize 
pain and discomfort to the animals and every effort was 
made to minimize animal suffering.
Thirty-two mice were divided into four groups randomly 
consisting of eight animals in each group (n = 8). Group 
A (control), received the vehicle (0.2% Tween 80 in 
normal saline). Group B received a single dose of CP at 
200 mg/kg b.w (body weight), i.p (intraperitoneally). 
Group C received farnesol in 5 mg/kg b.w, i.p for 7 days as 
pretreatment and following that a single dose of CP in 200 
mg/kg b.w, i.p. Group D received farnesol in 10 mg/kg b.w, 
i.p for 7 days as pretreatment and following that a single 
dose of CP in 200 mg/kg b.w, i.p.
Sampling
The blood sample (2 mL) was collected directly by cardiac 
puncture under light anesthesia, aspirated with sterile 
syringes without anticoagulant and centrifuged to separate 
the serum and was stored in microcentrifuge tubes. Then 
animals were euthanized and during necropsy, samples 
from different organs including liver, spleen, kidney, and 
testis were collected in separate containers containing 
10% neutral buffered formalin for histopathological 
examination. Some samples of testes from each group were 
stored at -80°C for further analysis. Blood samples were 
centrifuged (3000 rpm for 15 minutes at 4°C) to separate 
serum and stored at –80°C for subsequent analyses. 
Histopathologic analysis
After complete fixation of tissue samples from each 
group, the samples were processed in tissue processor. 
Then paraffin embedded blocks were prepared and cut in 
5-micron thickness using a microtome and were stained 
with hematoxylin and eosin (H&E) method. The stained 
samples were examined using a light microscope.
Biochemical analysis
For the demonstration of protective effects of farnesol 
against testicular injuries induced by CP, oxidative stress 
markers were investigated in testicular tissues. Thus, the 
testicular tissues were collected and rinsed with ice-cold 
saline and stored at -80°C. Before biochemical analysis, the 
tissues from testes were homogenized at 4°C after adding 
pre-cooled 0.9% saline in a ratio of 1: 9. When tissues were 
disrupted, the homogenates were centrifuged at 3000 rpm 
for 10 minutes at 4°C. The supernatants were used for 
biochemical measurements. Protein contents of the tissue 
homogenates were determined using the colorimetric 
method of Lowry et al with bovine serum albumin as the 
standard (14).
The formation of thiobarbituric acid in testicular 
samples were assessed to measure the lipid peroxidation, 
according to an original method (15) for determination 
of malondialdehyde (MDA) formation. Briefly, the 
supernatants of the tissue homogenates were mixed 
with 20% trichloroacetic acid and the mixtures were 
centrifuged. Then thiobarbituric acid was added to 
the supernatants and heated. The absorbance of the 
supernatants was measured at 532 nm. 
For catalase (CAT) analysis, 10% tissue homogenates were 
prepared in 2 mL of potassium phosphate buffer (pH 7.4). 
These homogenates were centrifuged at 3000 rpm for 15 
minutes. CAT activity was measured in the supernatants 
obtained after centrifugation. 2.95 mL of 19 mM H2O2 
was poured into the cuvettes. 0.05 mL of cytosolic 
supernatant was added to them and the changes in 240 
nm absorbance were recorded at 1 minute intervals for 3 
minutes. It is known that the presence of CAT decomposes 
H2O2 leading to a reduction in absorbance (16). 
The glutathione (GSH) contents were measured according 
to a previous study for measuring of total GSH (17). The 
tissues were rinsed 3 times with phosphate buffered 
saline (PBS). Tissue solutions were mixed with 20% 
15 
 
  
     (A)                                                                                    (B)              
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Fig2. Histopathological effect of farnesol on cellular liver toxicity of Cyclophosphamide (CP).  
1A- Normal structure of liver. 2A- In CP-treated mice, loss of hepatic architecture, degeneration and necrosis of 
hepatocytes (arrow) are seen. 3A- Amelioration in hepatic injuries is seen in the mice which received farnesol in 5 
Figure 1. Chemical structure of cyclophosphamide (A) and 
farnesol (B).
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trichloroacetic acid. The samples were centrifuged. The 
supernatants were mixed with 4 volume of Tris-buffered 
saline (TBS). Then, 1mM DTNB [(5, 5′-Dithiobis-
(2-nitrobenzoic acid)] was added to the samples and 
incubated for 30 minutes. The absorbance was read at 412 
nm.
The serum alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST), activities were determined by 
specific commercial kits, and expressed as unit per liter. 
All samples were tested in duplicate.
Statistical analysis
Results were expressed as mean ± SEM (standard error of 
mean) values. The data were analyzed by means of analysis 
of variance (ANOVA) followed by Duncan’s test. P values 
of <0.05 were considered as statistically significant. All the 
statistical analyses were done by SPSS version 16. 
Results
Histopathological evaluation
For histopathological evaluation of the protective 
properties of farnesol against cellular toxic effects of CP, 
tissue samples of livers, spleens, kidneys and testes were 
collected from each group and examined histologically, 
after processing. The results are presented in Figure 2.
Liver: In group A, microscopic examination showed 
normal histological structure (Figure 2, 1A). In group B, 
loss of hepatic architecture, moderate to severe diffuse 
vacuolar degeneration, necrotic hepatocytes, dilated and 
congested sinusoidal spaces, infiltration of mononuclear 
inflammatory cells between degenerated hepatocytes 
and moderate portal hepatitis were noted. In some 
areas, severe empty vacuoles associated with strands of 
necrotic hepatocytes were detected. Also, some dysplastic 
hepatocytes and large polymorphic and hyperchromatic 
hepatocyte were seen (Figure 2, 2A). Lower dose of 
farnesol (group C) did not prevent the toxic effects of CP, 
so, dilatation and congestion of sinusoids, coagulative 
necrotic areas, dysplastic hepatocytes were still present. 
In the mice of group D which received higher dose of 
farnesol, noticeably ameliorated hepatic injury induced 
by CP was observable. The liver demonstrated its normal 
histological structure relatively. Marked decrease of 
vacuolar degeneration and necrosis of most hepatocytes 
with minimized dysplastic changes, less dilation of central 
and portal veins, and obvious reduction of sinusoids 
congestion were noted. Regeneration of hepatocytes was 
detected by the presence of binucleated cells (Figure 2, 
3A and 4A).
Spleen: In group A, examination of sections of spleen 
revealed normal structure of red and white pulps (Figure 
3, 1B). In CP-treated mice, general disorganization and 
obvious loss in distinction between the red and white 
pulps were noted and also, decrease in the lymphocyte 
population, necrotic lymphocytes, congestion and 
increased hemosiderosis were seen (Figure 3, 2B). In group 
C, little improvement as apparent distinction between the 
red and white pulps was noted. A large number of the 
megakaryocytes and pigment-laden macrophages could 
also be detected in the red pulp accompanied with slight 
to marked atrophy of white pulp (Figure 3, 3B). In group 
D which received farnesol 10 mg/kg, the histopathological 
alterations were declined and a clear improvement was 
seen (Figure 3, 4B).
Kidney: In group A, histological examination of kidneys 
revealed normal architecture (Figure 4, 1C). In group B, 
administration a single dose of CP caused nephrotoxicity 
which was characterized by extensive degenerative 
Figure 2. Histopathological effect of farnesol on cellular liver toxicity of 
Cyclophosphamide (CP). 
1A- Normal structure of liver. 2A- In CP-treated mice, loss of hepatic 
architecture, degeneration and necrosis of hepatocytes (arrow) are 
seen. 3A- Amelioration in hepatic injuries is seen in the mice which 
received farnesol in 5 mg/kg (circle). 4A- In the mice which received 
farnesol in 10 mg/kg, the liver demonstrates its normal histological 
structure comparatively (circle). (H&E) ×100.
Figure 3. Histopathological effect of farnesol on spleen toxicity 
induced by cyclophosphamide (CP).
1B- Normal structure of red and white pulps of spleen. 2B- In CP-
treated mice, general disorganization, apparent loss of distinction 
between the red and white pulps and necrotic lymphocytes (arrows) 
were noted. 3B- Little improvement was seen as evident distinction 
between the red and white pulps in the mice which received farnesol in 
5 mg/kg. 4B- Obvious improvement was seen in the spleen structure 
of mice that received farnesol in 10 mg/kg. (H&E) ×100.
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changes, necrosis, desquamation of epithelial cells of 
tubules, shrinkage of the glomeruli and congestion (Figure 
4, 2C). The mice of group C and D which were respectively 
pretreated with farnesol 5 and 10 mg/kg, demonstrated 
no significant alleviation of renal injuries induced by CP 
(Figure 4, 3C and 4C).
Testis: In group A, the thick seminiferous epithelium 
with different stages of the spermatogenic cells and well-
developed Leydig cells in the interstitial spaces were 
observed (Figure 5, 1D). In the CP-treated mice, there 
was disorganization and distortion of the seminiferous 
tubules, vacuolization and moderated to severe atrophy 
of the seminiferous tubules. Degenerative and destructive 
sings were noted in both spermatogenic lineage and 
interstitial cells. The seminiferous epithelium was thinner 
compared with the control group. Congestion was noted 
in the interstitial tissue and under the tunica albuginea. 
Exfoliated germ cells and multinucleated giant were 
accumulated in the lumen of the tubules. The interstitial 
tissue was loosely packed around the seminiferous tubules 
(Figure 5, 2D). In group C, the severity of histopathologic 
lesions was lower in comparison with those in the mice of 
group B (Figure 5, 3D), but an advanced improvement was 
seen in the testes of mice treated with 10 mg/kg farnesol 
(group D). Most of the seminiferous tubules restored to its 
normal structure with the presence of all spermatogenic 
layers. The seminiferous tubules content of sperm and 
spermatocyte was relatively the same as with the control 
group. The number of Leydig cells increased and the 
nuclei of the Sertoli cells were returned to their natural 
shapes (Figure 5, 4D).
Biochemical evaluation
Because the testis showed the best response in the farnesol 
treated groups, so the oxidative stress markers were 
Figure 4. . Histopathological effect of farnesol on renal toxicity induced 
by Cyclophosphamide (CP).
1C- Normal structure of renal tubules. 2C- In CP-treated mice, there 
was extensive degenerative changes (arrows), necrosis (rectangle), 
desquamation of epithelial cells of tubules in the kidneys. 3C and 
4C- farnesol with 5 and 10 mg/kg could not alleviate the renal injuries 
induced by CP. Note  to degenerative changes in figure 3C and 3D 
(arrows). (H&E) ×100. 
Figure 5. Histopathological effect of farnesol on testis toxicity induced 
by Cyclophosphamide (CP).
1D- Normal structure of testis. Thick seminiferous epithelium was 
observed with different stages of the spermatogenic cells and Leydig 
cells in the interstitial spaces. 2D- In CP-treated mice, disorganization 
and distortion of the seminiferous tubules, vacuolization (arrows), 
moderate to severe atrophy of the seminiferous tubules were detected. 
3D- The severity of histopathologic lesions was less in testes of mice, 
which received farnesol in 5 mg/kg. 4D- Advanced improvement was 
seen in the testes of mice, which received farnesol in 10 mg/kg. (H&E) 
×100.
measured in its tissues. For evaluation of oxidative stress in 
testis, the amounts of MDA, GSH and CAT were compared 
between the control group (group A) and three other 
groups (B, C and D). The results of oxidative stress tests 
are presented in Table 1. The MDA after administration of 
CP in group B showed a marked increase compared to the 
control group (P < 0.01), but after using farnesol for 7 days 
as pretreatment in groups C (5 mg/kg) and D (10 mg/kg), 
the amount of MDA reduced, however significant decrease 
was only detected in group D (P < 0.05). Regarding GSH, 
the amount in control group (group A) was high, but after 
using CP in group B, the GSH decreased significantly 
(P < 0.05). After using farnesol as a pretreatment in groups 
C and D, the amount of GSH increased, however the 
significant increase was seen in group D compared to 
the CP group (P < 0.05). The level of CAT decreased after 
administration of CP, but following pretreatment with 
farnesol in groups C and D, the amount of CAT increased 
however; it was not statically significant (P > 0.05) 
For evaluation of hepatic injuries and showing protective 
properties of farnesol against cellular toxic effects of CP, 
AST and ALT were measured serum and compared in 
the groups. There were statistically significant differences 
(P < 0.05) between groups B and D and between A and B. 
The results are presented in Table 2. 
Discussion
CP is used as an antineoplastic agent for treatment 
of various cancers. This chemotherapeutic agent has 
several clinical side effects which have limited its clinical 
applications (18). Although, the mechanisms by which 
CP develop toxic effects are not well known, but several 
studies have demonstrated that these side effects may be 
attributable to interruption of redox stability of tissues 
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which result in oxidative stress and production of free 
radicals and reactive oxygen species (6,19). 
Acrolein, the main metabolite of CP, is responsible for 
producing free radicals through interaction with the 
body’s antioxidant defense system. The free radicals are 
highly reactive and cause oxidation of various enzymes 
(20). Acrolein leads to cellular damage after binding with 
the GSH  and reduction of its level in the cell (21). As a 
result, acrolein impairs the GSH dependent antioxidant 
system and amplifies free radical production (22). CP 
induces DNA damage through an oxidative process, 
which is caused by the generation of H2O2 (23). In the 
present study, the amount of GSH in CP-treated group 
decreased significantly (P < 0.05) and after using farnesol 
as pretreatment, the amount of GSH increased.
Membrane lipids have high susceptibility to damages 
induced by free radicals. Lipids after reacting with free 
radicals show lipid peroxidation (24). Lipid peroxidation 
is one of the main reasons of cyclophosphamide-
induced toxicity due to the production of acrolein. Lipid 
peroxidation is the fundamental factor of oxidative stress 
and MDA, a breakdown product of polyunsaturated fatty 
acid oxidation, is used as a marker of lipid peroxidation 
in tissues (1). In our study, the level of MDA after 
administration of CP demonstrated a marked increase 
compared to control group, but by using farnesol for 7 
days as pretreatment, the amount of MDA reduced. 
To avoid the side effects, CP is used in combination with 
various detoxifying agents like antioxidants. Free radical 
Table 1. Oxidative stress in testicular tissue in different treatment 
groups
Groups MDA (nmol/g)
GSH 
 (nmol/mg)
CAT  
(U/mg protein)
A (CON) 4.01 ± 0.82 0.91 ± 0.13 44.72 ± 5.2
B (CP) 8.28 ± 0.66a 0.52 ± 0.11a 33.22 ± 3.3a
C (CP+Far5) 6.28 ± 0.71 0.65 ± 0.11 36.27 ± 6.5
 D (CP+Far10) 5.08 ± 0.62b 0.77 ± 0.12b 39.1 ± 6.1
A (CON): Control group, B (CP): receiving cyclophosphamide, C 
(CP+Far5): receiving cyclophosphamide + farnesol 5 mg/kg, D 
(CP+Far10): receiving cyclophosphamide + farnesol 10 mg/kg. MDA: 
malondialdehyde; GSH: glutathione; CAT: catalase.
Values are expressed as mean ± SEM.  
a P < 0.05 in comparison with control group.
b P < 0.05 in comparison with CP group.
Table 2. The amounts of aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT) in different treated groups
Groups A (Control)  B (CP)  C (CP+Far5)  D (CP+Far10)
AST 189.28±10.71 250.57±7.40a 210.26±11.46 192±8.72b
ALT 116.2±22.94 148±24.73a 135±10.17` 110.1±9.46b
A (CON): Control group, B (CP): receiving cyclophosphamide, C 
(CP+Far5): receiving cyclophosphamide + farnesol 5 mg/kg, D 
(CP+Far10):   receiving cyclophosphamide + farnesol 10 mg/kg.
Values are expressed as mean ± SEM.  
a P < 0.05 in comparison with control group.
b P < 0.05 in comparison with CP group.
scavengers and antioxidants can be used as simultaneous 
treatment (11). In the present study, the level of CAT 
decreased after administration of CP, but following 
application of farnesol as pretreatment, the amount of 
CAT increased. Therefore, farnesol could be used as a 
pretreatment medicine before administration of CP to 
prevent CP toxic effects. 
The researchers have emphasized on the anticipatory 
effects of farnesol against hazardous materials. Qamar et 
al investigated the chemoprotective effects of farnesol in 
rats, which were intratracheally exposed to the carcinogen, 
benzo (a) pyrene. A pretreatment with farnesol was able to 
improve the inflammation, edema, surfactant dysfunction 
and injuries caused by this carcinogen (25).
Farnesol seems to be a very interesting and promising 
compound for its antioxidant, anti-inflammatory and 
chemopreventive properties. Khan and Sultana showed its 
anticipatory effect against DMH (1,2-dimethylhydrazine) 
-induced oxidative stress, inflammatory response and 
apoptosis in the colon of Wistar rats. The study indicated 
that a prophylactic treatment with farnesol could increase 
the antioxidant enzymes such as superoxide dismutase, 
CAT, GSH peroxidase, GSH reductase, glutathione-
S-transferase and quinone reductase and the cellular 
antioxidant-reduced GSH (12). 
In the present study, the testes had the best results in tissue 
restoration by using farnesol as pretreatment medication. 
Histopathological examination of testes showed the 
protective effect of farnesol. In group B the administration 
of CP produced tissue damage in testes, but in group D 
which received farnesol 10 mg/kg, the testicular injuries 
induced by CP was mitigated by farnesol completely. The 
deleterious effects of CP on testis have previously shown in 
other studies. In a study, single dose (200 mg/kg b.w, i.p) of 
CP injected to healthy male mice caused a very significant 
(P < 0.001) reduction in diverse spermatogonia cells in 
seminiferous tubules in comparison with control group 
(1). Several studies have shown testicular toxic effects of 
CP (26-28). Testicular toxicity may occur in result of the 
increase in the intracellular levels of ROS, which are toxic 
at high levels and can interact with macromolecules (1). In 
this study, farnesol as an antioxidant agent decreased the 
level of oxidative products and increased the tissue level 
of antioxidant enzymes. When the farnesol was used as 
a pretreatment medicine in treated groups, the amount 
of MDA decreased significantly in comparison with CP 
group (group B) but the antioxidant enzymes such as 
CAT and GSH increased. There is a common agreement 
that male reproductive organ is especially susceptible to 
the toxic effects of ROS and lipid peroxidation which 
eventually result in infertility and CP has a critical role 
in the production of these toxic agents (29,30). Farnesol 
was able to show an ameliorative effect on CP induced 
testicular injuries. In our previous study, our team has 
reported the protective effect of carvacrol, a terpenoid 
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compound, on ketamine induced testicular damage. Like 
farnesol, the protective effect of carvacrol was through its 
antioxidant properties (31). 
In this study, when farnesol was used as a pretreatment 
medicine, both liver and spleen showed tissue 
improvement. For the demonstration of regression of 
hepatic injuries induced by CP, the activities of the hepatic 
enzymes such as ALT and AST were evaluated. The 
activities of the hepatic enzymes such as ALT and AST in 
the plasma are reliable indicators of hepatic injuries (32). 
Elevated plasma levels of these enzymes by CP resulted 
from cellular damages and loss of functional integrity of 
hepatocyte membrane leading to their leakage into the 
serum or plasma (9). AST is an enzyme abundant in the 
cytoplasm and mitochondria of hepatocytes and presents 
in heart, skeletal muscle, and brain. ALT is a specific hepatic 
enzyme which principally is found in the cytoplasm of 
hepatocytes (33). Serologic results of this study showed 
that farnesol was able to produce hepatoprotective effect 
particularly when it was used at 10 mg/kg b.w, i.p. These 
results were compatible with histopathologic findings of 
this research, which confirmed the chemoprotective effect 
of farnesol against CP induced hepatic injuries.
Toxic metabolites produced during bioactivation of 
CP in the hepatocytes have an important role in CP 
induced nephrotoxicity (11). Additionally, renal cell 
damage induced by CP is caused after binding of acrolein 
with GSH and reduction of its level in cells (21). The 
nephrotoxicity of CP includes a variable reduction of 
glomerular filtration rate as well as tubular dysfunction 
(34). Histologically the CP treated rat kidneys showed 
glomerular nephritis, interstitial edema and cortical 
tubular vacuolization. Lysosomal enzymes activities 
decreased and protein content increased in the kidneys of 
CP treated rats. The reduction in the lysosomal enzymes 
activities, may contribute to renal damage (35). At this 
study, unfortunately there was not any significant healing 
in the kidneys of treated groups. This may be explained 
due to the severity of injuries induced by CP in renal 
tubular cells and glomeruli and the limited regeneration 
capacity of renal cells (11,36,37).
As a conclusion, farnesol as an antioxidant agent was able 
to provide some protection against toxic effects of CP, but 
for complete inhibition of CP induced tissue damages, 
the application of farnesol as a pretreatment medication 
requires more investigation with more details in future 
studies.
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